Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities ...
Read More
Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor, with cytotoxic regimens has led to survival benefits in cancer patients. This has raised important questions about the complexities inherent in the clinical application of angiogenesis inhibitors. Compiles the results of four decades of progress Integrating fundamental concepts with therapeutic strategies, Anti-Angiogenic Cancer Therapy promotes the idea that an understanding of the molecular and cellular regulation of angiogenesis leads to optimal therapeutic strategies and positive clinical results. It brings together contributions from leading researchers to provide the most authoritative and encyclopedic volume available on this subject. Examines the role of angiogenesis in cancer, including strategies to prolong the nonangiogenic dormant state of human tumors, molecular mechanisms and cellular regulation of angiogenesis in solid tumors and hematologic malignancies, and the regulation of angiogenesis by the tumor microenvironment. Covers specific molecular targets for inhibiting angiogenesis in cancer therapy. Discusses clinical trial design and translational research approaches essential for identifying and developing effective angiogenesis inhibitors. Outlines current understanding of the molecular biology of each cancer type followed by discussions that examine strategies for targeting angiogenesis in specific cancers. This volume celebrates progress made in four decades, and more importantly, it provi
Read Less
Add this copy of Antiangiogenic Cancer Therapy to cart. $75.10, new condition, Sold by Ingram Customer Returns Center rated 5.0 out of 5 stars, ships from NV, USA, published 2019 by CRC Press.
Add this copy of Antiangiogenic Cancer Therapy to cart. $92.91, new condition, Sold by Booksplease rated 4.0 out of 5 stars, ships from Southport, MERSEYSIDE, UNITED KINGDOM, published 2019 by CRC Press.
Add this copy of Antiangiogenic Cancer Therapy to cart. $101.72, new condition, Sold by Revaluation Books rated 4.0 out of 5 stars, ships from Exeter, DEVON, UNITED KINGDOM, published 2019 by CRC Pr I Llc.
Add this copy of Antiangiogenic Cancer Therapy to cart. $4.99, good condition, Sold by HPB-Red rated 5.0 out of 5 stars, ships from Dallas, TX, UNITED STATES, published 2007 by CRC Press.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
Good. Connecting readers with great books since 1972! Used textbooks may not include companion materials such as access codes, etc. May have some wear or writing/highlighting. We ship orders daily and Customer Service is our top priority!
Add this copy of Antiangiogenic Cancer Therapy to cart. $327.64, new condition, Sold by Booksplease rated 4.0 out of 5 stars, ships from Southport, MERSEYSIDE, UNITED KINGDOM, published 2007 by CRC Press Inc.